MIRVASO® In Use Study: Managing Rosacea Through Assessment and Control of Its Erythema (The MIRACLE Study)

NCT02249065 Phase 4 COMPLETED Results posted

This study is designed to: 1. assess the signs and symptoms of rosacea, including erythema, without treatment and during treatment with Mirvaso® gel 2. further characterize lifestyle impact and patient satisfaction with Mirvaso® treatment 3. gain a better understanding of the real-world use of Mirvaso® on the pattern and management of facial erythema of rosacea.

Details

Lead sponsor	Galderma R&D
Phase	Phase 4
Status	COMPLETED
Enrolment	205
Start date	2014-09
Completion	2015-08

Conditions

• Rosacea

Interventions

• Brimonidine

Primary outcomes

• Pre-Treatment Clinician Erythema Assessment (CEA) — 14 days (Day 1 (Baseline), Day 7, and Day 14/Exit)
  The number and percent of subjects in each CEA score category at each visit. CEA was conducted at the screening/baseline visit and all subsequent visits prior to the study drug application.

Countries

United States